Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer

(2014) A Mavrou et al.   ONCOGENE

Angiogenesis and anti-angiogenic therapy in prostate cancer

(2013) Deborah Mukherji et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

WT1 Mutants Reveal SRPK1 to Be a Downstream Angiogenesis Target by Altering VEGF Splicing

(2011) Elianna M. Amin et al.   CANCER CELL

Basic and Therapeutic Aspects of Angiogenesis

(2011) Michael Potente et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY

Multifocal prostate cancer: biologic, prognostic, and therapeutic implications

(2010) Matei Andreoiu et al.   HUMAN PATHOLOGY